Details of the Drug

General Information of Drug (ID: DMZ5RGV)

Drug Name
Naproxen
Synonyms
NAPROXEN; 22204-53-1; (S)-Naproxen; Naproxene; Naprosyn; (+)-Naproxen; Equiproxen; Laraflex; Naproxenum; Naproxeno; d-Naproxen; (S)-(+)-2-(6-Methoxy-2-naphthyl)propionic acid; (S)-(+)-Naproxen; Calosen; Nycopren; Naprosyne; Bonyl; Reuxen; Naixan; Axer; (+)-(S)-Naproxen; Ec-Naprosyn; (S)-2-(6-methoxynaphthalen-2-yl)propanoic acid; Flexipen; Clinosyn; Artrixen; Anexopen; Acusprain; Novonaprox; Arthrisil; Leniartil; Danaprox; Bipronyl; Artroxen; Napren; Naposin; Napflam; Genoxen; Daprox; Atiflan; Artagen; Apronax; Naprius; Nalyxan; Lefaine; Congex
Indication
Disease Entry ICD 11 Status REF
Osteoarthritis FA00-FA05 Approved [1]
Pain MG30-MG3Z Phase 2 [2], [3]
Endometriosis GA10 Investigative [4]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 230.26
Topological Polar Surface Area (xlogp) 3.3
Rotatable Bond Count (rotbonds) 3
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 3
ADMET Property
Absorption Tmax
The time to maximum plasma concentration (Tmax) is 1 h [5]
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [6]
Bioavailability
99% of drug becomes completely available to its intended biological destination(s) [7]
Clearance
The clearance of drug is 0.13 mL/min/kg [8]
Elimination
After oral administration, about 95% of naproxen and it's metabolites can be recovered in the urine with 66-92% recovered as conjugated metabolite and less than 1% recovered as naproxen or desmethylnaproxen [9]
Half-life
The concentration or amount of drug in body reduced by one-half in 12 - 17 hours [10]
Metabolism
The drug is metabolized via the liver [8]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 108.568 micromolar/kg/day [11]
Unbound Fraction
The unbound fraction of drug in plasma is 0.002% [12]
Vd
The volume of distribution (Vd) of drug is 0.16 L/kg [8]
Water Solubility
The ability of drug to dissolve in water is measured as 0.115 mg/mL [6]
Chemical Identifiers
Formula
C14H14O3
IUPAC Name
(2S)-2-(6-methoxynaphthalen-2-yl)propanoic acid
Canonical SMILES
C[C@@H](C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)O
InChI
InChI=1S/C14H14O3/c1-9(14(15)16)10-3-4-12-8-13(17-2)6-5-11(12)7-10/h3-9H,1-2H3,(H,15,16)/t9-/m0/s1
InChIKey
CMWTZPSULFXXJA-VIFPVBQESA-N
Cross-matching ID
PubChem CID
156391
ChEBI ID
CHEBI:7476
CAS Number
22204-53-1
DrugBank ID
DB00788
TTD ID
D0DJ1B
VARIDT ID
DR00603
INTEDE ID
DR1130
ACDINA ID
D00456

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Prostaglandin G/H synthase 1 (COX-1) TT8NGED PGH1_HUMAN Inhibitor [13]
Prostaglandin G/H synthase 2 (COX-2) TTVKILB PGH2_HUMAN Inhibitor [13], [4]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 2C9 (CYP2C9)
Main DME 		DE5IED8 CP2C9_HUMAN Substrate [14]
UDP-glucuronosyltransferase 1A1 (UGT1A1) DEYGVN4 UD11_HUMAN Substrate [15]
Cytochrome P450 1A2 (CYP1A2)
Main DME 		DEJGDUW CP1A2_HUMAN Substrate [16]
Cytochrome P450 2C8 (CYP2C8)
Main DME 		DES5XRU CP2C8_HUMAN Substrate [16]
UDP-glucuronosyltransferase 2B7 (UGT2B7) DEB3CV1 UD2B7_HUMAN Substrate [17]
UDP-glucuronosyltransferase 1A9 (UGT1A9) DE85D2P UD19_HUMAN Substrate [18]
UDP-glucuronosyltransferase 1A10 (UGT1A10) DEL5N6Y UD110_HUMAN Substrate [18]
UDP-glucuronosyltransferase 1A6 (UGT1A6) DESD26P UD16_HUMAN Substrate [18]
UDP-glucuronosyltransferase 1A3 (UGT1A3) DEF2WXN UD13_HUMAN Substrate [18]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Osteoarthritis
ICD Disease Classification FA00-FA05
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Prostaglandin G/H synthase 2 (COX-2) DTT PTGS2 7.93E-04 -0.29 -0.34
Prostaglandin G/H synthase 1 (COX-1) DTT PTGS1 3.97E-03 0.16 0.43
UDP-glucuronosyltransferase 1A1 (UGT1A1) DME UGT1A1 1.10E-01 -5.91E-02 -3.60E-01
Cytochrome P450 2C8 (CYP2C8) DME CYP2C8 1.82E-04 -1.35E-01 -5.84E-01
Cytochrome P450 1A2 (CYP1A2) DME CYP1A2 7.36E-01 1.62E-02 1.08E-01
Cytochrome P450 2C9 (CYP2C9) DME CYP2C9 1.90E-01 -9.81E-03 -5.96E-02
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Naproxen (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Remdesivir DMBFZ6L Moderate Increased risk of hepatotoxicity by the combination of Naproxen and Remdesivir. 1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019] [98]
Sodium bicarbonate DMMU6BJ Minor Decreased absorption of Naproxen due to altered gastric pH caused by Sodium bicarbonate. Acidosis [5C73] [99]
Repaglinide DM5SXUV Moderate Increased risk of hypoglycemia by the combination of Naproxen and Repaglinide. Acute diabete complication [5A2Y] [100]
Glibenclamide DM8JXPZ Moderate Increased risk of hypoglycemia by the combination of Naproxen and Glibenclamide. Acute diabete complication [5A2Y] [100]
Tolazamide DMIHRNA Moderate Increased risk of hypoglycemia by the combination of Naproxen and Tolazamide. Acute diabete complication [5A2Y] [100]
Glipizide DMZA5PQ Moderate Increased risk of hypoglycemia by the combination of Naproxen and Glipizide. Acute diabete complication [5A2Y] [100]
Arn-509 DMT81LZ Moderate Increased metabolism of Naproxen caused by Arn-509 mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [101]
Inotersen DMJ93CT Major Increased risk of bleeding by the combination of Naproxen and Inotersen. Amyloidosis [5D00] [101]
Bedaquiline DM3906J Moderate Increased risk of hepatotoxicity by the combination of Naproxen and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [102]
Cilostazol DMZMSCT Moderate Increased risk of bleeding by the combination of Naproxen and Cilostazol. Arterial occlusive disease [BD40] [103]
Budesonide DMJIBAW Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Naproxen and Budesonide. Asthma [CA23] [104]
Ofloxacin DM0VQN3 Moderate Additive CNS stimulant effects by the combination of Naproxen and Ofloxacin. Bacterial infection [1A00-1C4Z] [105]
Kanamycin DM2DMPO Moderate Increased risk of nephrotoxicity by the combination of Naproxen and Kanamycin. Bacterial infection [1A00-1C4Z] [106]
Sparfloxacin DMB4HCT Moderate Additive CNS stimulant effects by the combination of Naproxen and Sparfloxacin. Bacterial infection [1A00-1C4Z] [105]
Streptomycin DME1LQN Moderate Increased risk of nephrotoxicity by the combination of Naproxen and Streptomycin. Bacterial infection [1A00-1C4Z] [106]
Gemifloxacin DMHT34O Moderate Additive CNS depression effects by the combination of Naproxen and Gemifloxacin. Bacterial infection [1A00-1C4Z] [105]
Norfloxacin DMIZ6W2 Moderate Additive CNS stimulant effects by the combination of Naproxen and Norfloxacin. Bacterial infection [1A00-1C4Z] [105]
ABT-492 DMJFD2I Moderate Additive CNS depression effects by the combination of Naproxen and ABT-492. Bacterial infection [1A00-1C4Z] [105]
Gentamicin DMKINJO Moderate Increased risk of nephrotoxicity by the combination of Naproxen and Gentamicin. Bacterial infection [1A00-1C4Z] [106]
Rabeprazole DMMZXIW Moderate Decreased absorption of Naproxen due to altered gastric pH caused by Rabeprazole. Bacterial infection [1A00-1C4Z] [107]
Netilmicin DMRD1QK Moderate Increased risk of nephrotoxicity by the combination of Naproxen and Netilmicin. Bacterial infection [1A00-1C4Z] [106]
Levofloxacin DMS60RB Moderate Additive CNS stimulant effects by the combination of Naproxen and Levofloxacin. Bacterial infection [1A00-1C4Z] [105]
Lomefloxacin DMVRH9C Moderate Additive CNS stimulant effects by the combination of Naproxen and Lomefloxacin. Bacterial infection [1A00-1C4Z] [105]
Risedronate DM5FLTY Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Naproxen and Risedronate. Bone paget disease [FB85] [108]
Pexidartinib DMS2J0Z Major Increased risk of hepatotoxicity by the combination of Naproxen and Pexidartinib. Bone/articular cartilage neoplasm [2F7B] [109]
Lapatinib DM3BH1Y Moderate Decreased metabolism of Naproxen caused by Lapatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [110]
Alpelisib DMEXMYK Moderate Increased metabolism of Naproxen caused by Alpelisib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [111]
Trastuzumab Emtansine DMU1LXS Moderate Increased risk of bleeding by the combination of Naproxen and Trastuzumab Emtansine. Breast cancer [2C60-2C6Y] [103]
Iodipamide DMXIQYS Major Increased risk of nephrotoxicity by the combination of Naproxen and Iodipamide. Cholelithiasis [DC11] [112]
Levomilnacipran DMV26S8 Moderate Increased risk of bleeding by the combination of Naproxen and Levomilnacipran. Chronic pain [MG30] [113]
Regorafenib DMHSY1I Major Increased risk of bleeding by the combination of Naproxen and Regorafenib. Colorectal cancer [2B91] [101]
Drospirenone DM1A9W3 Moderate Increased risk of hyperkalemia by the combination of Naproxen and Drospirenone. Contraceptive management [QA21] [114]
Methoxyflurane DML0RAE Moderate Increased risk of nephrotoxicity by the combination of Naproxen and Methoxyflurane. Corneal disease [9A76-9A78] [101]
Ardeparin DMYRX8B Major Increased risk of bleeding by the combination of Naproxen and Ardeparin. Coronary thrombosis [BA43] [115]
Mifepristone DMGZQEF Moderate Decreased metabolism of Naproxen caused by Mifepristone mediated inhibition of CYP450 enzyme. Cushing syndrome [5A70] [116]
Osilodrostat DMIJC9X Moderate Decreased metabolism of Naproxen caused by Osilodrostat mediated inhibition of CYP450 enzyme. Cushing syndrome [5A70] [117]
Ivacaftor DMZC1HS Moderate Decreased metabolism of Naproxen caused by Ivacaftor mediated inhibition of CYP450 enzyme. Cystic fibrosis [CA25] [118]
MK-8228 DMOB58Q Moderate Increased metabolism of Naproxen caused by MK-8228 mediated induction of CYP450 enzyme. Cytomegaloviral disease [1D82] [119]
Danaparoid DM6CLBN Major Increased risk of bleeding by the combination of Naproxen and Danaparoid. Deep vein thrombosis [BD71] [115]
Rivaroxaban DMQMBZ1 Major Increased risk of bleeding by the combination of Naproxen and Rivaroxaban. Deep vein thrombosis [BD71] [120]
Sertraline DM0FB1J Moderate Increased risk of bleeding by the combination of Naproxen and Sertraline. Depression [6A70-6A7Z] [113]
Vortioxetine DM6F1PU Moderate Increased risk of bleeding by the combination of Naproxen and Vortioxetine. Depression [6A70-6A7Z] [113]
Milnacipran DMBFE74 Moderate Increased risk of bleeding by the combination of Naproxen and Milnacipran. Depression [6A70-6A7Z] [113]
Escitalopram DMFK9HG Moderate Increased risk of bleeding by the combination of Naproxen and Escitalopram. Depression [6A70-6A7Z] [113]
Clomipramine DMINRKW Moderate Increased risk of bleeding by the combination of Naproxen and Clomipramine. Depression [6A70-6A7Z] [113]
PMID28870136-Compound-49 DMTUC9E Moderate Increased risk of bleeding by the combination of Naproxen and PMID28870136-Compound-49. Discovery agent [N.A.] [121]
Cannabidiol DM0659E Moderate Increased risk of hepatotoxicity by the combination of Naproxen and Cannabidiol. Epileptic encephalopathy [8A62] [101]
Tazemetostat DMWP1BH Moderate Increased risk of bleeding by the combination of Naproxen and Tazemetostat. Follicular lymphoma [2A80] [103]
Dexlansoprazole DM1DBV5 Moderate Decreased absorption of Naproxen due to altered gastric pH caused by Dexlansoprazole. Gastro-oesophageal reflux disease [DA22] [107]
Ripretinib DM958QB Moderate Decreased clearance of Naproxen due to the transporter inhibition by Ripretinib. Gastrointestinal stromal tumour [2B5B] [98]
Avapritinib DMK2GZX Major Increased risk of bleeding by the combination of Naproxen and Avapritinib. Gastrointestinal stromal tumour [2B5B] [101]
Chlorothiazide DMLHESP Moderate Antagonize the effect of Naproxen when combined with Chlorothiazide. Heart failure [BD10-BD1Z] [122]
Bumetanide DMRV7H0 Moderate Antagonize the effect of Naproxen when combined with Bumetanide. Heart failure [BD10-BD1Z] [122]
Rifapentine DMCHV4I Moderate Increased metabolism of Naproxen caused by Rifapentine mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [123]
Brentuximab vedotin DMWLC57 Moderate Increased risk of hepatotoxicity by the combination of Naproxen and Brentuximab vedotin. Hodgkin lymphoma [2B30] [124]
Etravirine DMGV8QU Moderate Decreased metabolism of Naproxen caused by Etravirine mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [125]
Fenofibrate DMFKXDY Moderate Decreased metabolism of Naproxen caused by Fenofibrate mediated inhibition of CYP450 enzyme. Hyper-lipoproteinaemia [5C80] [98]
Mipomersen DMGSRN1 Major Increased risk of hepatotoxicity by the combination of Naproxen and Mipomersen. Hyper-lipoproteinaemia [5C80] [126]
Teriflunomide DMQ2FKJ Major Increased risk of hepatotoxicity by the combination of Naproxen and Teriflunomide. Hyper-lipoproteinaemia [5C80] [127]
BMS-201038 DMQTAGO Major Increased risk of hepatotoxicity by the combination of Naproxen and BMS-201038. Hyper-lipoproteinaemia [5C80] [128]
Indapamide DMGN1PW Moderate Antagonize the effect of Naproxen when combined with Indapamide. Hypertension [BA00-BA04] [122]
Trichlormethiazide DMHAQCO Moderate Antagonize the effect of Naproxen when combined with Trichlormethiazide. Hypertension [BA00-BA04] [122]
Dipyridamole DMXY30O Moderate Increased risk of bleeding by the combination of Naproxen and Dipyridamole. Hypertension [BA00-BA04] [103]
Givosiran DM5PFIJ Moderate Decreased metabolism of Naproxen caused by Givosiran mediated inhibition of CYP450 enzyme. Inborn porphyrin/heme metabolism error [5C58] [129]
Balsalazide DMO091F Moderate Increased risk of nephrotoxicity by the combination of Naproxen and Balsalazide. Indeterminate colitis [DD72] [130]
PF-06463922 DMKM7EW Moderate Increased metabolism of Naproxen caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [98]
Capmatinib DMYCXKL Moderate Decreased metabolism of Naproxen caused by Capmatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [131]
Selpercatinib DMZR15V Moderate Decreased metabolism of Naproxen caused by Selpercatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [101]
Calaspargase pegol DMQZBXI Moderate Increased risk of bleeding by the combination of Naproxen and Calaspargase pegol. Malignant haematopoietic neoplasm [2B33] [132]
Idelalisib DM602WT Moderate Increased risk of hepatotoxicity by the combination of Naproxen and Idelalisib. Mature B-cell leukaemia [2A82] [133]
Acalabrutinib DM7GCVW Major Increased risk of bleeding by the combination of Naproxen and Acalabrutinib. Mature B-cell lymphoma [2A85] [134]
Ibrutinib DMHZCPO Major Increased risk of bleeding by the combination of Naproxen and Ibrutinib. Mature B-cell lymphoma [2A85] [135]
Ponatinib DMYGJQO Major Increased risk of bleeding by the combination of Naproxen and Ponatinib. Mature B-cell lymphoma [2A85] [136]
Arry-162 DM1P6FR Moderate Decreased clearance of Naproxen due to the transporter inhibition by Arry-162. Melanoma [2C30] [98]
Vemurafenib DM62UG5 Moderate Decreased metabolism of Naproxen caused by Vemurafenib mediated inhibition of CYP450 enzyme. Melanoma [2C30] [98]
Dabrafenib DMX6OE3 Moderate Increased metabolism of Naproxen caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [101]
Exjade DMHPRWG Major Increased risk of nephrotoxicity by the combination of Naproxen and Exjade. Mineral absorption/transport disorder [5C64] [137]
Panobinostat DM58WKG Major Increased risk of bleeding by the combination of Naproxen and Panobinostat. Multiple myeloma [2A83] [98]
Deflazacort DMV0RNS Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Naproxen and Deflazacort. Muscular dystrophy [8C70] [104]
Ruxolitinib DM7Q98D Moderate Increased risk of bleeding by the combination of Naproxen and Ruxolitinib. Myeloproliferative neoplasm [2A20] [103]
Dasatinib DMJV2EK Major Increased risk of bleeding by the combination of Naproxen and Dasatinib. Myeloproliferative neoplasm [2A20] [138]
Omacetaxine mepesuccinate DMPU2WX Major Increased risk of bleeding by the combination of Naproxen and Omacetaxine mepesuccinate. Myeloproliferative neoplasm [2A20] [139]
Prasugrel DM7MT6E Major Increased risk of bleeding by the combination of Naproxen and Prasugrel. Myocardial infarction [BA41-BA43] [101]
Vorapaxar DMA16BR Major Increased risk of bleeding by the combination of Naproxen and Vorapaxar. Myocardial infarction [BA41-BA43] [140]
Sibutramine DMFJTDI Moderate Increased risk of bleeding by the combination of Naproxen and Sibutramine. Obesity [5B80-5B81] [113]
Dexfenfluramine DMJ7YDS Moderate Increased risk of bleeding by the combination of Naproxen and Dexfenfluramine. Obesity [5B80-5B81] [113]
Polythiazide DMCH80F Moderate Antagonize the effect of Naproxen when combined with Polythiazide. Oedema [MG29] [122]
Rucaparib DM9PVX8 Moderate Decreased metabolism of Naproxen caused by Rucaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [141]
MK-4827 DMLYGH4 Moderate Increased risk of bleeding by the combination of Naproxen and MK-4827. Ovarian cancer [2C73] [101]
Aspirin DM672AH Moderate Increased risk of bleeding by the combination of Naproxen and Aspirin. Pain [MG30-MG3Z] [142]
Abametapir DM2RX0I Moderate Decreased metabolism of Naproxen caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [143]
Enzalutamide DMGL19D Moderate Increased metabolism of Naproxen caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [144]
Iloprost DMVPZBE Moderate Increased risk of bleeding by the combination of Naproxen and Iloprost. Pulmonary hypertension [BB01] [145]
Everolimus DM8X2EH Major Increased risk of nephrotoxicity by the combination of Naproxen and Everolimus. Renal cell carcinoma [2C90] [146]
Temsirolimus DMS104F Major Increased risk of nephrotoxicity by the combination of Naproxen and Temsirolimus. Renal cell carcinoma [2C90] [146]
Gatifloxacin DMSL679 Moderate Additive CNS stimulant effects by the combination of Naproxen and Gatifloxacin. Respiratory infection [CA07-CA4Z] [105]
Sulfasalazine DMICA9H Moderate Increased risk of nephrotoxicity by the combination of Naproxen and Sulfasalazine. Rheumatoid arthritis [FA20] [130]
Dexamethasone DMMWZET Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Naproxen and Dexamethasone. Rheumatoid arthritis [FA20] [104]
Leflunomide DMR8ONJ Major Increased risk of hepatotoxicity by the combination of Naproxen and Leflunomide. Rheumatoid arthritis [FA20] [127]
Methylprednisolone DM4BDON Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Naproxen and Methylprednisolone. Solid tumour/cancer [2A00-2F9Z] [104]
Trabectedin DMG3Y89 Moderate Increased risk of hepatotoxicity by the combination of Naproxen and Trabectedin. Solid tumour/cancer [2A00-2F9Z] [101]
Prednisolone DMQ8FR2 Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Naproxen and Prednisolone. Solid tumour/cancer [2A00-2F9Z] [104]
Pitolisant DM8RFNJ Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Naproxen and Pitolisant. Somnolence [MG42] [101]
Lusutrombopag DMH6IKO Moderate Decreased clearance of Naproxen due to the transporter inhibition by Lusutrombopag. Thrombocytopenia [3B64] [141]
Caplacizumab DMPUKA7 Moderate Increased risk of bleeding by the combination of Naproxen and Caplacizumab. Thrombocytopenia [3B64] [103]
Apixaban DM89JLN Major Increased risk of bleeding by the combination of Naproxen and Apixaban. Thrombosis [DB61-GB90] [101]
Cangrelor DM8JRH0 Moderate Increased risk of bleeding by the combination of Naproxen and Cangrelor. Thrombosis [DB61-GB90] [103]
Brilinta DMBR01X Moderate Increased risk of bleeding by the combination of Naproxen and Brilinta. Thrombosis [DB61-GB90] [101]
Cabozantinib DMIYDT4 Major Increased risk of bleeding by the combination of Naproxen and Cabozantinib. Thyroid cancer [2D10] [147]
Tacrolimus DMZ7XNQ Major Increased risk of nephrotoxicity by the combination of Naproxen and Tacrolimus. Transplant rejection [NE84] [146]
Olsalazine DMZW9HA Moderate Increased risk of nephrotoxicity by the combination of Naproxen and Olsalazine. Ulcerative colitis [DD71] [130]
Plazomicin DMKMBES Moderate Increased risk of nephrotoxicity by the combination of Naproxen and Plazomicin. Urinary tract infection [GC08] [106]
Betrixaban DM2C4RF Major Increased risk of bleeding by the combination of Naproxen and Betrixaban. Venous thromboembolism [BD72] [148]
⏷ Show the Full List of 113 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Allura red AC dye E00338 33258 Colorant
FD&C blue no. 1 E00263 19700 Colorant
FD&C blue no. 2 E00446 2723854 Colorant
Fumaric acid E00420 444972 Acidulant; Antioxidant; Complexing agent; Flavoring agent; Solubilizing agent
Glyceryl monostearate E00310 24699 Emollient; Emulsifying agent; Emulsion stabilizing agent; Solubilizing agent; Surfactant; Viscosity-controlling agent
Kyselina citronova E00014 311 Acidulant; Antioxidant; Buffering agent; Complexing agent; Flavoring agent
Lactic acid E00020 612 Acidulant
Mannitol E00103 6251 Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
Quinoline yellow WS E00309 24671 Colorant
Sodium lauryl sulfate E00464 3423265 Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Stearic acid E00079 5281 Emulsifying agent; Solubilizing agent; Viscosity-controlling agent; lubricant
Sunset yellow FCF E00255 17730 Colorant
Carmellose sodium E00625 Not Available Disintegrant
Citric acid monohydrate E00271 22230 Acidulant; Antioxidant; Buffering agent; Complexing agent; Flavoring agent
Crospovidone E00626 Not Available Disintegrant
Edetate disodium E00186 8759 Complexing agent
Eisenoxyd E00585 56841934 Colorant
Ferric hydroxide oxide yellow E00539 23320441 Colorant
Ferrosoferric oxide E00231 14789 Colorant
Glycerin E00026 753 Antimicrobial preservative; Emollient; Flavoring agent; Humectant; Lubricant; Plasticizing agent; Solvent; Suppository base; Tonicity agent; Viscosity-controlling agent
Hexahydric alcohol E00083 5780 Diluent; Flavoring agent; Humectant; Plasticizing agent
Hypromellose E00634 Not Available Coating agent
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Magnesium sulfate E00281 24083 Vaccine adjuvant
Polyethylene glycol 1000 E00647 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 3350 E00652 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 400 E00653 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 6000 E00655 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polysorbate 80 E00665 Not Available Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Polyvinyl alcohol E00666 Not Available Coating agent; Emulsion stabilizing agent; Film/Membrane-forming agent
Povidone E00667 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Propylene glycol E00040 1030 Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Sodium hydroxide E00234 14798 Alkalizing agent
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Triethyl citrate E00128 6506 Plasticizing agent; Solvent
Vinylpyrrolidone E00668 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Water E00035 962 Solvent
⏷ Show the Full List of 40 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Naproxen 220 mg capsule 220 mg Oral Capsule Oral
Naproxen 220 mg tablet 220 mg Oral Tablet Oral
Naproxen 550 mg tablet 550 mg Oral Tablet Oral
Naproxen 750 mg tablet 750 mg 24 HR Extended Release Oral Tablet Oral
Naproxen 500 mg tablet 500 mg 24 HR Extended Release Oral Tablet Oral
Naproxen 200 mg tablet 200 mg Oral Tablet Oral
Naproxen 275 mg tablet 275 mg Oral Tablet Oral
Naproxen 375 mg tablet 375 mg 24 HR Extended Release Oral Tablet Oral
Naproxen 250 mg tablet 250 mg Oral Tablet Oral
Naproxen 375 mg tablet 375 mg Oral Tablet Oral
Naproxen 500 mg tablet 500 mg Oral Tablet Oral
Naproxen 375 mg tablet 375 mg Delayed Release Oral Tablet Oral
Naproxen 500 mg tablet 500 mg Delayed Release Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5230).
3 ClinicalTrials.gov (NCT01139190) Clinical Trial Evaluating Gastrointestinal Damage Following Administration PL3100 or Naproxen in At-Risk Adults. U.S. National Institutes of Health.
4 New drugs in development for the treatment of endometriosis. Expert Opin Investig Drugs. 2008 Aug;17(8):1187-202.
5 Todd PA, Clissold SP: Naproxen. A reappraisal of its pharmacology, and therapeutic use in rheumatic diseases and pain states. Drugs. 1990 Jul;40(1):91-137. doi: 10.2165/00003495-199040010-00006.
6 BDDCS applied to over 900 drugs
7 Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
8 Naprelan FDA Label
9 Falany CN, Strom P, Swedmark S: Sulphation of o-desmethylnaproxen and related compounds by human cytosolic sulfotransferases. Br J Clin Pharmacol. 2005 Dec;60(6):632-40. doi: 10.1111/j.1365-2125.2005.02506.x.
10 Naproxen .
11 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
12 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
13 Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. J Clin Pharmacol. 2000 Oct;40(10):1109-20.
14 Drug interactions in dentistry: the importance of knowing your CYPs. J Am Dent Assoc. 2004 Mar;135(3):298-311.
15 Influence of mutations associated with Gilbert and Crigler-Najjar type II syndromes on the glucuronidation kinetics of bilirubin and other UDP-glucuronosyltransferase 1A substrates. Pharmacogenet Genomics. 2007 Dec;17(12):1017-29.
16 Involvement of multiple cytochrome P450 isoforms in naproxen O-demethylation. Eur J Clin Pharmacol. 1997;52(4):293-8.
17 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
18 S-Naproxen and desmethylnaproxen glucuronidation by human liver microsomes and recombinant human UDP-glucuronosyltransferases (UGT): role of UGT2B7 in the elimination of naproxen. Br J Clin Pharmacol. 2005 Oct;60(4):423-33.
19 Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
20 Effects of polyunsaturated fatty acids on prostaglandin synthesis and cyclooxygenase-mediated DNA adduct formation by heterocyclic aromatic amines in human adenocarcinoma colon cells. Mol Carcinog. 2004 Jul;40(3):180-8.
21 Endoxifen and other metabolites of tamoxifen inhibit human hydroxysteroid sulfotransferase 2A1 (hSULT2A1). Drug Metab Dispos. 2014 Nov;42(11):1843-50.
22 Cytochrome P450 1A2 (CYP1A2) activity and risk factors for breast cancer: a cross-sectional study. Breast Cancer Res. 2004;6(4):R352-65.
23 PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses. Pharmacogenet Genomics. 2015 Aug;25(8):416-26.
24 The effect of apigenin on pharmacokinetics of imatinib and its metabolite N-desmethyl imatinib in rats. Biomed Res Int. 2013;2013:789184.
25 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
26 The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
27 Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1993 Sep;348(3):332-7.
28 Metabolism and metabolic inhibition of xanthotoxol in human liver microsomes. Evid Based Complement Alternat Med. 2016;2016:5416509.
29 Functional significance of UDP-glucuronosyltransferase variants in the metabolism of active tamoxifen metabolites. Cancer Res. 2009 Mar 1;69(5):1892-900.
30 Functional characterization of human and cynomolgus monkey UDP-glucuronosyltransferase 1A1 enzymes. Life Sci. 2010 Aug 14;87(7-8):261-8.
31 Effect of UDP-glucuronosyltransferase (UGT) 1A polymorphism (rs8330 and rs10929303) on glucuronidation status of acetaminophen. Dose Response. 2017 Sep 11;15(3):1559325817723731.
32 UDP-glucuronosyltransferase 1A1 is the principal enzyme responsible for etoposide glucuronidation in human liver and intestinal microsomes: structural characterization of phenolic and alcoholic glucuronides of etoposide and estimation of enzyme kinetics. Drug Metab Dispos. 2007 Mar;35(3):371-80.
33 Interindividual variability in pharmacokinetics of generic nucleoside reverse transcriptase inhibitors in TB/HIV-coinfected Ghanaian patients: UGT2B7*1c is associated with faster zidovudine clearance and glucuronidation. J Clin Pharmacol. 2009 Sep;49(9):1079-90.
34 Effect of aging on glucuronidation of valproic acid in human liver microsomes and the role of UDP-glucuronosyltransferase UGT1A4, UGT1A8, and UGT1A10. Drug Metab Dispos. 2009 Jan;37(1):229-36.
35 Characterization of rat intestinal microsomal UDP-glucuronosyltransferase activity toward mycophenolic acid. Drug Metab Dispos. 2006 Sep;34(9):1632-9.
36 Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos. 2004 Nov;32(11):1201-8.
37 Substrate-dependent modulation of UDP-glucuronosyltransferase 1A1 (UGT1A1) by propofol in recombinant human UGT1A1 and human liver microsomes. Basic Clin Pharmacol Toxicol. 2007 Sep;101(3):211-4.
38 Identification and preliminary characterization of UDP-glucuronosyltransferases catalyzing formation of ethyl glucuronide. Anal Bioanal Chem. 2014 Apr;406(9-10):2325-32.
39 Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241.
40 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
41 Differential expression and function of CYP2C isoforms in human intestine and liver. Pharmacogenetics. 2003 Sep;13(9):565-75.
42 Analysis of human cytochrome P450 2C8 substrate specificity using a substrate pharmacophore and site-directed mutants. Biochemistry. 2004 Dec 14;43(49):15379-92.
43 Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study. Cancer Chemother Pharmacol. 2011 Nov;68(5):1111-8.
44 PharmGKB summary: mycophenolic acid pathway. Pharmacogenet Genomics. 2014 Jan;24(1):73-9.
45 Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
46 Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
47 Tamoxifen inhibits cytochrome P450 2C9 activity in breast cancer patients. J Chemother. 2006 Aug;18(4):421-4.
48 Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98.
49 Drug-drug interactions with imatinib: an observational study. Medicine (Baltimore). 2016 Oct;95(40):e5076.
50 Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos. 2000 Feb;28(2):125-30.
51 New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I. Curr Drug Metab. 2009 Dec;10(10):1075-126.
52 A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat. 2003 Dec;82(3):191-7.
53 A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
54 Metabolism and transport of tamoxifen in relation to its effectiveness: new perspectives on an ongoing controversy. Future Oncol. 2014 Jan;10(1):107-22.
55 Determination of UDP-glucuronosyltransferase UGT2B7 activity in human liver microsomes by ultra-performance liquid chromatography with MS detection. J Chromatogr B Analyt Technol Biomed Life Sci. 2008 Jul 1;870(1):84-90.
56 Pharmacokinetic and pharmacodynamic interaction of lorazepam and valproic acid in relation to UGT2B7 genetic polymorphism in healthy subjects. Clin Pharmacol Ther. 2008 Apr;83(4):595-600.
57 Pitavastatin: a review in hypercholesterolemia. Am J Cardiovasc Drugs. 2017 Apr;17(2):157-168.
58 Troglitazone glucuronidation in human liver and intestine microsomes: high catalytic activity of UGT1A8 and UGT1A10. Drug Metab Dispos. 2002 Dec;30(12):1462-9.
59 Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. Clin Pharmacokinet. 2005;44(5):467-94.
60 Pharmacogenomics of statins: understanding susceptibility to adverse effects. Pharmgenomics Pers Med. 2016 Oct 3;9:97-106.
61 Glucuronidation of nonsteroidal anti-inflammatory drugs: identifying the enzymes responsible in human liver microsomes. Drug Metab Dispos. 2005 Jul;33(7):1027-35.
62 UGT1A1*28 is associated with decreased systemic exposure of atorvastatin lactone. Mol Diagn Ther. 2013 Aug;17(4):233-7.
63 Cerivastatin, genetic variants, and the risk of rhabdomyolysis. Pharmacogenet Genomics. 2011 May;21(5):280-8.
64 Drug interactions between the immunosuppressant tacrolimus and the cholesterol absorption inhibitor ezetimibe in healthy volunteers. Clin Pharmacol Ther. 2011 Apr;89(4):524-8.
65 Polymorphic expression of UGT1A9 is associated with variable acetaminophen glucuronidation in neonates: a population pharmacokinetic and pharmacogenetic study. Clin Pharmacokinet. 2018 Oct;57(10):1325-1336.
66 Pharmacokinetic interaction involving sorafenib and the calcium-channel blocker felodipine in a patient with hepatocellular carcinoma. Invest New Drugs. 2011 Dec;29(6):1511-4.
67 The evolution of population pharmacokinetic models to describe the enterohepatic recycling of mycophenolic acid in solid organ transplantation and autoimmune disease. Clin Pharmacokinet. 2011 Jan;50(1):1-24.
68 The UDP-glucuronosyltransferase 1A9 enzyme is a peroxisome proliferator-activated receptor alpha and gamma target gene. J Biol Chem. 2003 Apr 18;278(16):13975-83.
69 UGT1A6 and UGT2B15 polymorphisms and acetaminophen conjugation in response to a randomized, controlled diet of select fruits and vegetables. Drug Metab Dispos. 2011 Sep;39(9):1650-7.
70 UDP glucuronosyltransferase (UGT) 1A6 pharmacogenetics: II. Functional impact of the three most common nonsynonymous UGT1A6 polymorphisms (S7A, T181A, and R184S). J Pharmacol Exp Ther. 2005 Jun;313(3):1340-6.
71 Pharmacokinetics of propofol and extrahepatic UGT1A6 gene expression in anhepatic rats. Pharmacology. 2009;84(4):219-26.
72 Polymorphisms of Aspirin-Metabolizing Enzymes CYP2C9, NAT2 and UGT1A6 in Aspirin-Intolerant Urticaria. Allergy Asthma Immunol Res. 2011 Oct;3(4):273-6.
73 Deferiprone glucuronidation by human tissues and recombinant UDP glucuronosyltransferase 1A6: an in vitro investigation of genetic and splice variants. Drug Metab Dispos. 2009 Feb;37(2):322-9.
74 Structural and functional studies of UDP-glucuronosyltransferases. Drug Metab Rev. 1999 Nov;31(4):817-99.
75 Human UGT1A6 pharmacogenetics: identification of a novel SNP, characterization of allele frequencies and functional analysis of recombinant allozymes in human liver tissue and in cultured cells. Pharmacogenetics. 2004 Aug;14(8):487-99.
76 Identification of aspartic acid and histidine residues mediating the reaction mechanism and the substrate specificity of the human UDP-glucuronosyltransferases 1A. J Biol Chem. 2007 Dec 14;282(50):36514-24.
77 Glucuronidation of active tamoxifen metabolites by the human UDP glucuronosyltransferases. Drug Metab Dispos. 2007 Nov;35(11):2006-14.
78 [Pharmacology of mycophenolate mofetil: recent data and clinical consequences]. Nephrologie. 2001;22(7):331-7.
79 Characterization of raloxifene glucuronidation: potential role of UGT1A8 genotype on raloxifene metabolism in vivo. Cancer Prev Res (Phila). 2013 Jul;6(7):719-30.
80 In vitro metabolism, permeability, and efflux of bazedoxifene in humans. Drug Metab Dispos. 2010 Sep;38(9):1471-9.
81 UDP-glucuronosyltransferases and clinical drug-drug interactions. Pharmacol Ther. 2005 Apr;106(1):97-132.
82 The C50T polymorphism of the cyclooxygenase-1 gene and the risk of thrombotic events during low-dose therapy with acetyl salicylic acid. Thromb Haemost. 2008 Jul;100(1):70-5.
83 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
84 Cox-2 inhibitory effects of naturally occurring and modified fatty acids. J Nat Prod. 2001 Jun;64(6):745-9.
85 Comparison of cyclooxygenase inhibitory activity and ocular anti-inflammatory effects of ketorolac tromethamine and bromfenac sodium. Curr Med Res Opin. 2006 Jun;22(6):1133-40.
86 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
87 Ouellet M, Percival MD: Effect of inhibitor time-dependency on selectivity towards cyclooxygenase isoforms. Biochem J. 1995 Feb 15;306 ( Pt 1):247-51.
88 Differential binding mode of diverse cyclooxygenase inhibitors. J Mol Graph Model. 2002 Mar;20(5):359-71.
89 Differential metabolism of dihomo-gamma-linolenic acid and arachidonic acid by cyclo-oxygenase-1 and cyclo-oxygenase-2: implications for cellular synthesis of prostaglandin E1 and prostaglandin E2. Biochem J. 2002 Jul 15;365(Pt 2):489-96.
90 Fenbufen based 3-[5-(substituted aryl)-1,3,4-oxadiazol-2-yl]-1-(biphenyl-4-yl)propan-1-ones as safer antiinflammatory and analgesic agents. Eur J Med Chem. 2009 Sep;44(9):3798-804.
91 Maternal toxicity of nonsteroidal anti-inflammatory drugs as an important factor affecting prenatal development. Reprod Toxicol. 2009 Sep;28(2):239-44.
92 Membranous nephropathy associated with the relatively selective cyclooxygenase-2 inhibitor, etodolac, in a patient with early rheumatoid arthritis. Intern Med. 2007;46(13):1055-8.
93 Pfizer. Product Development Pipeline. March 31 2009.
94 Renal effects of nabumetone, a COX-2 antagonist: impairment of function in isolated perfused rat kidneys contrasts with preserved renal function in vivo. Exp Nephrol. 2001;9(6):387-96.
95 Privileged structures: a useful concept for the rational design of new lead drug candidates. Mini Rev Med Chem. 2007 Nov;7(11):1108-19.
96 Flurbiprofen, a cyclooxygenase inhibitor, protects mice from hepatic ischemia/reperfusion injury by inhibiting GSK-3 signaling and mitochondrial permeability transition.Mol Med.2012 Sep 25;18:1128-35.
97 Dissociation of airway inflammation and hyperresponsiveness by cyclooxygenase inhibition in allergen challenged mice. Eur Respir J. 2009 Jul;34(1):200-8.
98 Cerner Multum, Inc. "Australian Product Information.".
99 Brogden RN, Heel RC, Speight TM, Avery GS "Naproxen up to date: a review of its pharmacological properties and therapeutic efficacy and use in rheumatic diseases and pain states." Drugs 18 (1979): 241-77. [PMID: 387372]
100 Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D "Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia." Br J Clin Pharmacol 52 (2001): 456-7. [PMID: 11678792]
101 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
102 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
103 Product Information. Acular (ketorolac). Allergan Inc, Irvine, CA.
104 Buchman AL, Schwartz MR "Colonic ulceration associated with the systemic use of nonsteroidal antiinflammatory medication." J Clin Gastroenterol 22 (1996): 224-6. [PMID: 8724264]
105 Product Information. Factive (gemifloxacin). GeneSoft Inc, San Francisco, CA.
106 Assael BM, Chiabrando C, Gagliardi L, Noseda A, Bamonte F, Salmona M "Prostaglandins and aminoglycoside nephrotoxicity." Toxicol Appl Pharmacol 78 (1985): 386-94. [PMID: 4049389]
107 Product Information. Naprosyn (naproxen). Syntex Laboratories Inc, Palo Alto, CA.
108 Product Information. Actonel (risedronate). Procter and Gamble Pharmaceuticals, Cincinnati, OH.
109 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
110 Product Information. Tykerb (lapatinib). Novartis Pharmaceuticals, East Hanover, NJ.
111 Product Information. Piqray (alpelisib). Novartis Pharmaceuticals, East Hanover, NJ.
112 Wong GT, Lee EY, Irwin MG. Contrast induced nephropathy in vascular surgery.?Br J Anaesth. 2016;117 Suppl 2:ii63-ii73. [PMID: 27566809]
113 Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992): 1517-9. [PMID: 1482806]
114 Product Information. Yasmin (drospirenone-ethinyl estradiol) Berlex Laboratories, Richmond, CA.
115 Bang CJ, Riedel B, Talstad I, Berstad A "Interaction between heparin and acetylsalicylic acid on gastric mucosal and skin bleeding in humans." Scand J Gastroenterol 27 (1992): 489-94. [PMID: 1321488]
116 Product Information. Korlym (mifepristone). Corcept Therapeutics Incorporated, Menlo Park, CA.
117 Product Information. Isturisa (osilodrostat). Recordati Rare Diseases Inc, Lebanon, NJ.
118 Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
119 Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
120 Product Information. Xarelto (rivaroxaban). Bayer Inc, Toronto, IA.
121 Canadian Pharmacists Association.
122 Muller FO, Schall R, Devaal AC, Groenewoud G, Hundt HKL, Middle MV "Influence of meloxicam on furosemide pharmacokinetics and pharmacodynamics in healthy volunteers." Eur J Clin Pharmacol 48 (1995): 247-51. [PMID: 7589049]
123 Product Information. Priftin (rifapentine). Hoechst Marion-Roussel Inc, Kansas City, MO.
124 Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA.
125 Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
126 Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
127 EMEA "EMEA public statement on leflunomide (ARAVA) - severe and serious hepatic reactions.".
128 Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
129 Product Information. Givlaari (givosiran). Alnylam Pharmaceuticals, Cambridge, MA.
130 Novis BH, Korzets Z, Chen P, Bernheim J "Nephrotic syndrome after treatment with 5-aminosalicylic acid." Br Med J (Clin Res Ed) 296 (1988): 1442. [PMID: 3132281]
131 Product Information. Tabrecta (capmatinib). Novartis Pharmaceuticals, East Hanover, NJ.
132 Caruso V, Iacoviello L, Di Castelnuovo A, et.al "Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients." Blood 108 (2006): 2216-22. [PMID: 16804111]
133 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
134 Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
135 Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
136 Product Information. Iclusig (ponatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
137 Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
138 Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
139 Product Information. Brukinsa (zanubrutinib). BeiGene USA, Inc, San Mateo, CA.
140 Product Information. Zontivity (vorapaxar). Merck & Company Inc, Whitehouse Station, NJ.
141 EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
142 Concomitant use of ibuprofen and aspirin. J Pain Palliat Care Pharmacother 21 (2007): 73-4. [PMID: 17844731]
143 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
144 Benoist G, van Oort I, et al "Drug-drug interaction potential in men treated with enzalutamide: Mind the gap." Br J Clin Pharmacol 0 (2017): epub. [PMID: 28881501]
145 Product Information. Flolan (epoprostenol). Glaxo Wellcome, Research Triangle Park, NC.
146 Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
147 Product Information. Cometriq (cabozantinib). Exelixis Inc, S San Francisco, CA.
148 Product Information. Bevyxxa (betrixaban). Portola Pharmaceuticals, South San Francisco, CA.